NDAORALTABLET
Approved
Jun 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
6/8 — Strong
EXFORGE (amlodipine besylate and valsartan) by Novartis is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 2007.
Drug data last refreshed 17h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXFORGE is a fixed-dose oral combination of amlodipine besylate (calcium channel blocker) and valsartan (ARB) approved in 2007 for hypertension management. It works by relaxing blood vessels through dual mechanism: blocking angiotensin II receptors and inhibiting calcium influx into vascular smooth muscle. Patients typically receive this tablet when monotherapy is insufficient for blood pressure control.
$2MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with minimal Part D presence ($2M spending, 3,063 claims in 2023) signals a contracted brand team focused on maintenance rather than growth initiatives.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers
Started Jul 2012
51 enrolled
Healthy Male Volunteer
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
Started May 2010
564 enrolled
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
Started Jan 2007
698 enrolled
Hypertension
Career Relevance
EXFORGE currently has zero linked job openings, reflecting its mature, declining commercial status. Career opportunities on this product are primarily in cost containment, market access negotiations, and defending modest volume against generics—not growth or innovation roles. This assignment is typically a stepping stone to higher-impact products rather than a destination role.
Worked on EXFORGE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.